Wyeth Pharmaceuticals Limited

MAIDENHEAD, England - - Study Published in Rheumatology Underscores the Need for Early and Aggressive Treatment to Maintain Work Productivity Patients receiving Enbrel(R) (etanercept) in combination with methotrexate for early RA are more likely to continue working, according to the COMET study published today in Rheumatology.

MAIDENHEAD, England - Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).

MAIDENHEAD, England - - Prevenar Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Worldwide Israel has initiated a national immunisation programme (NIP) against pneumococcal disease with Wyeth Pharmaceuticals' vaccine Prevenar(tm) (Pneumococcal Saccharide Conjugated Vaccine, [Adsorbed]) - which helps protect infants and young children against the serotypes contained in the vaccine.

MAIDENHEAD, England - Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing Spondylitis Indicated Improvement in Patients With and Without Peripheral Joint Involvement - Results From PRESTA Study in Psoriatic Arthritis Indicated Improvement in Joint and Skin Symptoms Analyses of data from three studies provide insight into the use of ENBREL(R) (etanercept) in the treatment of three conditions for which ENBREL is indicated: moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

MAIDENHEAD, England - CHMP Recommends Approval of a Continuous Dosing Regimen Option for Enbrel In Plaque Psoriasis, and a New Pre-Filled Pen Delivery Device Today, Wyeth received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for two recent submissions relating to Enbrel(R) (etanercept), the tumour necrosis factor alpha inhibitor treatment for plaque psoriasis, rheumatoid arthritis and other related inflammatory conditions.